Trump's 200% Tariff Threats Shake Pharma Supply Chains

US President Donald Trump threatens a 200% tariff on pharmaceuticals, alarming industry and global supply chains. Trump hints at a year to comply, followed by steep tariffs. Industry warns of counterproductive effects on US healthcare and the complex process of onshoring. Chartered Institute of Export & International Trade expresses concerns about disrupting global pharmaceutical supply chains.

Pharma stocks remain stable despite the tariff threat, with slight drops in major companies. Ireland, a key producer for the US market, could be impacted. Irish medical exports to the US surged over 450% in February 2025. Other major suppliers include India and China, with investments in US manufacturing facilities to mitigate potential tariffs.

Pharmaceutical companies are investing in US manufacturing sites to offset potential tariffs. Eli Lilly plans to invest $27bn, with Novartis, Sanofi, and others following suit. Trump’s tariff threat could have far-reaching consequences on global pharmaceutical supply chains, prompting industry players to strategize and adapt to the changing landscape.

Read more at Yahoo Finance: Trump’s 200% tariff threat could send shockwaves through pharma supply chains